Literature DB >> 20971063

Connective tissue growth factor is a substrate of ADAM28.

Satsuki Mochizuki1, Rena Tanaka, Masayuki Shimoda, Junko Onuma, Yutaka Fujii, Hiromitsu Jinno, Yasunori Okada.   

Abstract

ADAM28, a member of the ADAM (a disintegrin and metalloproteinase) gene family, is over-expressed by carcinoma cells and the expression correlates with carcinoma cell proliferation and progression in human lung and breast carcinomas. However, information about substrates of ADAM28 is limited. We screened interacting molecules of ADAM28 in human lung cDNA library by yeast two-hybrid system and identified connective tissue growth factor (CTGF). Binding of CTGF to proADAM28 was demonstrated by yeast two-hybrid assay and protein binding assay. ADAM28 cleaved CTGF in dose- and time-dependent manners at the Ala(181)-Tyr(182) and Asp(191)-Pro(192) bonds in the hinge region of the molecule. ADAM28 selectively digested CTGF in the complex of CTGF and vascular endothelial growth factor(165) (VEGF(165)), releasing biologically active VEGF(165) from the complex. RT-PCR and immunohistochemical analyses demonstrated that ADAM28, CTGF and VEGF are commonly co-expressed in the breast carcinoma tissues. These data provide the first evidence that CTGF is a novel substrate of ADAM28 and suggest that ADAM28 may promote VEGF(165)-induced angiogenesis in the breast carcinomas by the CTGF digestion in the CTGF/VEGF(165) complex.
Copyright © 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20971063     DOI: 10.1016/j.bbrc.2010.10.077

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  12 in total

1.  Connective tissue growth factor (CCN2) is a matricellular preproprotein controlled by proteolytic activation.

Authors:  Ole Jørgen Kaasbøll; Ashish K Gadicherla; Jian-Hua Wang; Vivi Talstad Monsen; Else Marie Valbjørn Hagelin; Meng-Qiu Dong; Håvard Attramadal
Journal:  J Biol Chem       Date:  2018-09-27       Impact factor: 5.157

Review 2.  Extracellular regulation of VEGF: isoforms, proteolysis, and vascular patterning.

Authors:  Prakash Vempati; Aleksander S Popel; Feilim Mac Gabhann
Journal:  Cytokine Growth Factor Rev       Date:  2013-11-27       Impact factor: 7.638

3.  Pasteurella multocida toxin (PMT) upregulates CTGF which leads to mTORC1 activation in Swiss 3T3 cells.

Authors:  Hammou Oubrahim; Allison Wong; Brenda A Wilson; P Boon Chock
Journal:  Cell Signal       Date:  2013-02-13       Impact factor: 4.315

4.  ADAM28 is elevated in humans with the metabolic syndrome and is a novel sheddase of human tumour necrosis factor-α.

Authors:  Jeremy B M Jowett; Yasunori Okada; Peter J Leedman; Joanne E Curran; Matthew P Johnson; Eric K Moses; Harald H H Goring; Satsuki Mochizuki; John Blangero; Leah Stone; Holly Allen; Chris Mitchell; Vance B Matthews
Journal:  Immunol Cell Biol       Date:  2012-09-25       Impact factor: 5.126

5.  Baseline and decline of serum ADAM28 during chemotherapy of advanced non-small cell lung cancer: a probable predictive and prognostic factor.

Authors:  Yan-ling Lv; Dong-mei Yuan; Qing-bo Wang; Ping Zhan; Liang Luo; Tang-feng Lv; Hong-bing Liu; Yu-feng Li; Jian Wen; Yong Song
Journal:  Med Oncol       Date:  2012-02-22       Impact factor: 3.064

Review 6.  The CCN2/CTGF interactome: an approach to understanding the versatility of CCN2/CTGF molecular activities.

Authors:  Viktor Zaykov; Brahim Chaqour
Journal:  J Cell Commun Signal       Date:  2021-10-06       Impact factor: 5.782

7.  Enhancer RNA and NFκB-dependent P300 regulation of ADAMDEC1.

Authors:  Lihua Shi; Song Li; Kelly Maurer; Zhe Zhang; Michelle Petri; Kathleen E Sullivan
Journal:  Mol Immunol       Date:  2018-10-20       Impact factor: 4.407

8.  The ADAMs family of proteases: new biomarkers and therapeutic targets for cancer?

Authors:  Michael J Duffy; Maeve Mullooly; Norma O'Donovan; Sumainizah Sukor; John Crown; Aisling Pierce; Patricia M McGowan
Journal:  Clin Proteomics       Date:  2011-06-09       Impact factor: 3.988

Review 9.  Contribution of ADAM17 and related ADAMs in cardiovascular diseases.

Authors:  Tatsuo Kawai; Katherine J Elliott; Rosario Scalia; Satoru Eguchi
Journal:  Cell Mol Life Sci       Date:  2021-02-11       Impact factor: 9.207

10.  Overexpression and knock-down studies highlight that a disintegrin and metalloproteinase 28 controls proliferation and migration in human prostate cancer.

Authors:  Caroline Rudnicka; Satsuki Mochizuki; Yasunori Okada; Claire McLaughlin; Peter J Leedman; Lisa Stuart; Michael Epis; Gerard Hoyne; Sherif Boulos; Liam Johnson; Markus Schlaich; Vance Matthews
Journal:  Medicine (Baltimore)       Date:  2016-10       Impact factor: 1.889

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.